公开(公告)号：WO2010124042A3

公开(公告)日：2011-02-03

申请号：PCT/US2010031974

申请日：2010-04-22

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

Inventor： WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

IPC: C07D498/04 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

CPC classification number: C07D498/04 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1,4]苯并二氮杂，1,2,3,4,4a， 7-八氢吡嗪并[1,2-a] [1,5]苯并二氮杂，2,3,4,4a，5,6,7,11b-八氢-1H-吡啶并[3,4-d] [2]苯并氮杂， 1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1]苯并氮杂，1,2,3,4,4a，5-六氢-7H-吡嗪并[1,2 -a] [4,1]苯并氧氮杂和2,3,4,4a，5,6-六氢-1H-吡嗪并[2,1-d] [1,5]苯并氧氮杂和5,6,7,7a ，其中R 1，R 2，R 3，R 4，R 5，R 6，R 6，R 5，R 6， X1，X2，X3，X4，Y1，Y2和Y3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：CA2759607A1

公开(公告)日：2010-10-28

申请号：CA2759607

申请日：2010-04-22

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

IPC: C07D498/04 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：MX2011011182A

公开(公告)日：2012-02-21

申请号：MX2011011182

申请日：2010-04-22

Applicant: ABBOTT LAB

Inventor： DJURIC STEVAN W ,  BRAJE WILFRIED ,  WANG YING ,  BREWER JASON T ,  AKRITOPOULOUZANZE IRINI ,  POHLKI FRAUKE ,  RELO ANA-LUCIA

IPC: C07D498/04 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

Abstract: La presente solicitud se refiere a derivados de 1,2,3,4,4a,5,6,7-octahidropirazino[1,2-a][1,4]benzodiazepina, 1,2,3,4,4a,5,6,7-octahidropirazino[1,2-a][1,5]benzodiazepina, 2,3,4,4a,5,6,7,11b-octahidro-1H-pirido[3,4-d][2]benzazepina, 1,2,3,4,4a,5,6,7-octahidropirazino[1,2-aJ[1]benzazepina, 1,2,3,4,4a,5-hexahidro-7H-pirazino[1,2-a][4,1]benzoxazepina, y 2,3,4,4a,5,6-hexahidro-1H-pirazino[2,1-d][1,5]benzoxazepina, y 5,6,7,7a,8,9,10,11-octahidropirazino[1,2-d]pirido[3,2-b][1,4]diaz epina de la fórmula (I) en la cual R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, y Y3 son como se definen en la descripción. La presente solicitud también se refiere a composiciones que comprenden dichos compuestos, y a métodos para tratar condiciones patológicas utilizando dichos compuestos y composiciones, y a métodos para identificar dichos compuestos.